Comparing chemo and immunotherapy before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial looks at whether adding immunotherapy to chemotherapy before surgery helps people with triple-negative breast cancer. It compares different treatment approaches to see which works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with triple-negative breast cancer.
- You have completed neoadjuvant therapy (treatment before surgery).
- You had surgery after neoadjuvant therapy and have pathology results from that surgery.
- You have not had cancer before or received chemotherapy or immunotherapy in the past.
- You do not have cancer in both breasts or cancer that has spread to other parts of the body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
This trial tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy, before surgery, can improve treatment for early triple-negative breast cancer. It compares two chemotherapy approaches—one with anthracyclines and one without—to see which works better when combined with toripalimab.
This trial tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. The treatment is given before surgery to shrink the tumor and make surgery more effective.
This study compares a new drug (JS004) added to an immunotherapy and chemotherapy combination versus the usual immunotherapy plus chemotherapy or chemotherapy alone. It aims to see if adding this new drug can shrink breast cancer more effectively before surgery.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
Hear when a new TNBC, Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.